New Era for Autoimmune T-Cell Engagers Takes Centre Stage This October

Autoimmune T-Cell Engager Field Reaches Defining Moment as Industry Leaders Prepare to Unite in Boston

Boston, MA | October 27–29, 2026

The autoimmune T-cell engager field is entering a pivotal new phase, as drug developers move beyond oncology-derived molecules and towards purpose-built therapies designed specifically for autoimmune disease.

With critical challenges emerging around precision immune-cell depletion, cytokine release syndrome mitigation, translational predictability, and durable immune reset, the 2nd T-Cell Engager for Autoimmune Disease Summit is set to unite the leaders shaping the next generation of autoimmune T-cell engager development.

Taking place October 27–29 in Boston, this is the industry’s only dedicated summit focused exclusively on T-cell engagers for autoimmune disease, bringing together 80+ discovery, translational, preclinical, clinical, and business leaders for three days of technical case studies, scientific discussion, and high-value networking.

As momentum builds across the field, attendees will gain direct access to the companies and experts driving progress in next-generation target discovery, precision immune modulation, co-stimulatory engineering, translational strategy, and clinical advancement.

Featured speakers include:

• Jeffrey Jones, Chief Medical Officer, Cullinan Therapeutics
• Giovanni Abbadessa, Chief Medical Officer, ModeX Therapeutics
• Mohamed Hassanein, Senior Director, Immunology, Eli Lilly & Co.
• Shinji Okitsu, Strategic Collaborations & Partnerships Head of Research, Sanofi
• Mike Jones, Search & Evaluation Lead, GI & Inflammation, Strategy & Portfolio Development, Takeda Pharmaceutical
• Yi Yang, Director, Novartis AG
• Sarah Leonard, Interim Chief Executive Officer, T-Cypher Bio
• David de Graaf, Co-Founder, Chief Executive Officer & President, Reverb Therapeutics
• Marvin Gee, Chief Research Officer & Co-Founder, 3T Biosciences
• Naresh Kumar, Director, Bioscience Immunology, AstraZeneca

With autoimmune T-cell engager programs accelerating and new scientific challenges emerging, this summit provides a timely forum for drug developers to benchmark strategy, pressure-test approaches, and uncover the insights needed to differentiate and advance their pipelines.

The full event brochure is now available to download: https://ter.li/g5ko81xz

Book before Friday, August 7 to secure your biggest saving of up to $1,000

You can secure your place today: https://ter.li/aa085lw1